Sigma-Aldrich Corp

Sigma-Aldrich — Q1 2012 Earnings Presentation

17 slides from Sigma-Aldrich's earnings presentation, Apr 24, 2012

  1. Slide 1: Sigma-Aldrich Corporation Q1 2012 Earnings Review & Outlook

    • Sigma-Aldrich Corporation Q1 2012 Earnings Review & Outlook Enabling Science to Improve the Quality of Life sigma-aldrich.com Exhibit 99.2

  2. Slide 2: Cautionary Statements

    • • Cautionary Statements O ur presentation today may include forward-looking statements within the meaning of Section 27A of the Securities Act of and Section 21E of the Securities Exchange Act of 1934. Such statements involve risk and uncertainty, including financial, business environment and proj

  3. Slide 3: 1st Quarter 2012 Financial Results

    YEAR-OVER-YEAR Sales of $665 Million Increase 5% Over Last Year Sales and Operating Income New Quarterly Highs YEAR-OVER-YEAR 1st Quarter 2012 Financial Results ($ in millions, except per share amounts) As Reported Q1 2012 As Reported Excluding Special Items Operating Income $ 172 3% 4% Net Income $

  4. Slide 4: Sales Mix (QTD) Organic Sales Growth in Line with Expectations

    Sales Mix (QTD) Organic Sales Growth in Line with Expectations 2012 Sales Growth RESEARCH 70% 30% SAFC 4% 1% 3% Research SAFC Total Company Organic* Reported 4% 9% 5% Q1 2012 / Q1 2011 *See Slide 16 for Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth. 2% 9% 4% Acquisitions

  5. Slide 5: Growth Initiatives Collectively on Track

    00 Growth. Initiatives Collectively on Track Q1 2012 Sales Performance Highlight Innovation Reported Organic (1) • Analytical, Biology, Materials Science Sales Growth (2) 4-8% 3-9% Geographic Growth • North America 5% 1% • Europe 1% 2% • Asia Pacific/Latin America 13% 9% • Focus Markets – India, Chi

  6. Slide 6: Adjusted Operating Margin Analysis

    Adjusted Operating Margin, Excluding the Impact of Acquisitions, Improved 00 Reported Operating Income Margin to Adjusted Operating Income Ma rgin. 26.6% Margin Analysis PERCENTAGE OF SALES Q1 2012 Adjusted Operating Income Margin – Q1 26.9% Adjusted Operating Income Before Acquisitions (1) (1) (1)

  7. Slide 7: Free Cash Flow: Working Capital and Capital Expenditures Increase

    3 Months Ended March 31 Working Capital and Capital Expenditures Increase to Support Sales Growth and Improve Operational Efficiency Free Cash Flow (in millions) $ 117 (56) (32) $ 112 Net Income Free Cash Flow Net Cash Provided by Operating Activities Less Capital Expenditures Other Changes in Perfo

  8. Slide 8: First Quarter 2012 Highlights

    Q1 Results Meet Expectations; Acquisition and New Capacity to Boost Sales Growth • Record quarter for sales and earnings • Acquisition of BioReliance and Research Organics • New Capacity First Quarter 2012 Highlights

  9. Slide 9: Sigma-Aldrich Positioned to Capitalize on These Market Trends

    Sigma-Aldrich Positioned to Capitalize on These Market Trends • Macro-economic Pressures • Industry Consolidation • Outsourcing in Pharmaceutical • Emerging Market Growth • Shift to Biologics • Applied Markets Growth Key Trends Drive Opportunities

  10. Slide 10: Organic Sales Growth and EPS Outlook Reaffirmed

    Organic Sales Growth and EPS Outlook Reaffirmed 2012 Guidance Organic Sales Growth 1st Half Mid Single-digit 2nd Half Full Year Low Double-digits Low to Mid Single-digit Research SAFC Mid Single-digit Low to Mid Single-digit Diluted Adjusted EPS* Free Cash Flow $ 3.90 to $ 4.05 Approximately $425M *

  11. Slide 11: Questions?

    QUESTIONS? Sigma-Aldrich Corporation Q1 2012 Earnings Review

  12. Slide 12: Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures

    Appendix Reconciliation of GAAP to Non-GAAP Financial Measures

  13. Slide 13: Net Income and Diluted Earnings Per Share to Adjusted

    Reconciliation of Reported Net Income and Diluted Earnings Per Share to Adjusted Net Income and Adjusted Diluted Earnings Per Share (Unaudited) Reported net income $ $ 0.96 $ 0.97 $ Acquisition transaction costs - 0.03 - Restructuring costs - - 0.01 Tax Benefit - (5) - (0.04) Adjusted net income $ $

  14. Slide 14: Operating Income to Adjusted Operating Income

    Reconciliation of Reported Operating Income to Adjusted Operating Income (Unaudited) Reported operating income $ $ Acquisition transaction costs - Restructuring costs - Adjusted operating income $ $ Reported operating income margin 25.9% 26.4% Acquisition transaction costs 0.7% - Restructuring costs

  15. Slide 15: Sales Growth to Adjusted (Organic) Sales Growth

    Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth (Unaudited) Three Months Ended March 31, Reported FX Impact Acquisitions Organic • Analytical, Biology, Materials Science Sales Growth Geographic Growth • North America • Europe • Asia Pacific/Latin America • Focus Markets –

  16. Slide 16: Sales Growth to Adjusted (Organic) by Business Unit

    Reconciliation of Reported Sales Growth to Adjusted (Organic) Sales Growth (Unaudited) Sales Growth by Business Unit Currency Acquisition Adjusted Reported Benefit Benefit (Organic) Research Chemicals 4% (2%) 2% 4% SAFC 9% (1%) 9% 1% Total Customer Sales 5% (2%) 4% 3% Three Months Ended March 31, 20

  17. Slide 17: Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow

    Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited) In millions Net cash provided by operating activities $ $ Less: Capital expenditures (32) (18) Free cash flow $ $ March 31, Three Months Ended

Sigma-Aldrich — Q1 2012 Earnings Presentation on 6ix